European Regulators Begin Accelerated Review of AstraZeneca's COVID-19 Vaccine Candidate, but FDA Widens Its Investigation Into Clinical Trial Illness
According to a Bloomberg article published Thursday morning, the European Medicines Agency (EMA) has begun a rolling review of AZD1222, the COVID-19 vaccine candidate being jointly developed by AstraZeneca (NYSE: AZN) and the University of Oxford.
A rolling review is one in which regulators analyze data from clinical trials that are still underway in order to determine whether they should approve a drug or vaccine. Such reviews are reserved for emergency situations; the coronavirus pandemic certainly qualifies. The EMA had previously stated it would conduct rolling reviews of promising vaccine candidates.
Image source: Getty Images.
Source Fool.com
